Diana V. Do
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diana V. Do has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Quan Dong Nguyen
Byers Eye Institute, Stanford University School of Medicine, Palo Alto, USA
10 shared publications - Yasir Jamal Sepah
Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, USA
7 shared publications Quan Dong Nguyen
Stanford University School of Medicine
6 shared publications- Amir Akhavanrezayat
Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA
4 shared publications Angela S. Li
Duke Univ, Dept Ophthalmol, Durham, NC USA
4 shared publications- Muhammad Sohail Halim
Byers Eye Institute, Stanford University, Palo Alto, CA, USA
4 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Springer Nature in Eye
- p. 1-2
Infographic: Efficacy and safety of high-dose intravitreal aflibercept 8 mg in patients with diabetic macular oedema: week 96 results from the phase 2/3 PHOTON trial
- 7 August 2026
- Published by Springer Nature in Eye
- p. 1-2
Open AccessInfographic: Efficacy and safety of high-dose intravitreal aflibercept 8 mg in patients with diabetic macular oedema: week 96 results from the phase 2/3 PHOTON trial
- Top Cited PapersOpen Access
- 1 May 2026
- Published by Wolters Kluwer Health in Retina
- Vol. 46 (5) , 783-795
LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS)
Purpose: To evaluate the safety and efficacy of multiwavelength photobiomodulation (PBM) in nonexudative (dry) age-related macular degeneration (AMD). Methods: LIGHTSITE III used a double-masked, randomized, sham-controlled, parallel-group, prospective study design. Subjects were enrolled with a diagnosis of dry AMD and treated with multiwavelength PBM (Valeda Light Delivery System; 590, 660, and 850 nm) or sham treatment. A treatment series included 9 PBM or sham treatments delivered 3x/week over 3 to 5 weeks every 4 months (M) for 24M. Results: A total of 148 eyes (100 subjects) with dry AMD were randomized into the study. LIGHTSITE III met the prespecified primary BCVA efficacy end point at M21 with a significant difference between treatment groups ( P = 0.0036) and a +6.2 letter gain after PBM. At M21, 61.5% of PBM-treated eyes showed ≥5, 23.1% showed ≥10, and 4.4% showed ≥15 letter gains. A favorable safety profile was observed with no signs of phototoxicity. Disease progression to Geographic Atrophy (GA) showed a significant decrease in incidence (Sham, 24.0% vs. PBM, 6.8%; P = 0.007) after PBM treatment at M24. Significant benefit in vision QoL was observed. Conclusion: Multiwavelength PBM represents an interventional therapy that restores visual function and has potential disease-modifying effects in intermediate dry AMD.
- 1 May 2026
- Published by Wolters Kluwer Health in Retina
- Vol. 46 (5) , 783-795
Top Cited PapersOpen AccessLONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS)
Purpose: To evaluate the safety and efficacy of multiwavelength photobiomodulation (PBM) in nonexudative (dry) age-related macular degeneration (AMD). Methods: LIGHTSITE III used a double-masked, randomized, sham-controlled, parallel-group, prospective study design. Subjects were enrolled with a diagnosis of dry AMD and treated with multiwavelength PBM (Valeda Light Delivery System; 590, 660, and 850 nm) or sham treatment. A treatment series included 9 PBM or sham treatments delivered 3x/week over 3 to 5 weeks every 4 months (M) for 24M. Results: A total of 148 eyes (100 subjects) with dry AMD were randomized into the study. LIGHTSITE III met the prespecified primary BCVA efficacy end point at M21 with a significant difference between treatment groups ( P = 0.0036) and a +6.2 letter gain after PBM. At M21, 61.5% of PBM-treated eyes showed ≥5, 23.1% showed ≥10, and 4.4% showed ≥15 letter gains. A favorable safety profile was observed with no signs of phototoxicity. Disease progression to Geographic Atrophy (GA) showed a significant decrease in incidence (Sham, 24.0% vs. PBM, 6.8%; P = 0.007) after PBM treatment at M24. Significant benefit in vision QoL was observed. Conclusion: Multiwavelength PBM represents an interventional therapy that restores visual function and has potential disease-modifying effects in intermediate dry AMD.
- 25 December 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (7) , 805-808
Analysis of full-field electroretinography parameters and potential for monitoring functional retinal deterioration in unilateral retinal vasculitis
To elucidate changes of full-field electroretinography (ffERG) tests in active unilateral retinal vasculitis, using the unaffected fellow eye as an internal control. Despite no significant differences in best corrected visual acuity (p=0.100) or central subfield macular thickness (p=0.084) at baseline, ffERG showed significant reductions in five of eight amplitudes (i.e. DA10 a-wave, p<0.001) and delays in six of eight implicit times (i.e. light-adapted Flicker, p=0.002). At follow-up ffERG, following management for retinal vasculitis, the implicit times normalised, coinciding with inflammation reduction. However, the amplitude reductions persisted. In ffERG, the implicit time might be a sensitive biomarker for retinal vasculitis activity and the amplitude might be one for permanent functional loss.
- 25 December 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (7) , 805-808
Analysis of full-field electroretinography parameters and potential for monitoring functional retinal deterioration in unilateral retinal vasculitis
To elucidate changes of full-field electroretinography (ffERG) tests in active unilateral retinal vasculitis, using the unaffected fellow eye as an internal control. Despite no significant differences in best corrected visual acuity (p=0.100) or central subfield macular thickness (p=0.084) at baseline, ffERG showed significant reductions in five of eight amplitudes (i.e. DA10 a-wave, p<0.001) and delays in six of eight implicit times (i.e. light-adapted Flicker, p=0.002). At follow-up ffERG, following management for retinal vasculitis, the implicit times normalised, coinciding with inflammation reduction. However, the amplitude reductions persisted. In ffERG, the implicit time might be a sensitive biomarker for retinal vasculitis activity and the amplitude might be one for permanent functional loss.
- Open Access
- 11 November 2025
- Published by Elsevier in Ophthalmology
- Vol. 133 (5) , 577-588
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema
- 11 November 2025
- Published by Elsevier in Ophthalmology
- Vol. 133 (5) , 577-588
Open AccessIntravitreal Aflibercept 8 mg for Diabetic Macular Edema
- Open Access
- 29 April 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (5) , 655
Development of Rifampicin Eye Drops for the Treatment of Exudative Age-Related Macular Degeneration
Background/Objectives: Exudative age-related macular degeneration (AMD) is a disease of choroidal neovascularization that causes blindness. Current treatments to preserve vision in this prevalent and blinding condition are repeat intraocular injections of anti-vascular endothelial growth factor medicines for a patient’s lifetime to preserve and prevent vision loss leading to blindness. Rifampicin, a small-molecule antibiotic, has previously been reported to exhibit anti-angiogenic properties and a topical safety profile that is well-tolerated. Based on this evidence, we investigated the feasibility of formulating rifamycin as an ophthalmic drop capable of delivering therapeutic concentrations to the posterior segment of the eye. Methods: Inhibition of neovascularization by administration of rifampicin was analyzed in the rat oxygen-induced retinopathy (OIR) and mouse laser-induced choroidal neovascularization (CNV) models. Pharmacokinetic (PK) studies were conducted in mice, rats, and rabbits by dosing various formulations containing rifampicin, and the compound was quantified by LC/MS analysis. Results: Results from dose escalation studies in the mouse laser-induced CNV model suggested the minimum effective dose of rifampicin required for inhibiting neovascularization in subretinal tissues to be 0.7 mg/kg, which is substantially lower than the 20 mg/kg dosage approved for infectious disease treatments. The previous studies did not report the minimum effective dose in the anti-angiogenesis effects. The effective area under the concentration-time curve (AUC) in the sub-retina was evaluated as 0.27 h·ng/mg. In rabbits, rifampicin was delivered to the sub-retina by a single topical application of various formulations in a dose-dependent manner. The topical application of the formulations containing 1% rifampicin, which was well-tolerated in clinical trials previously reported for ocular trachoma, achieved subretinal delivery approximately 2–32 times greater than the effective AUC. Plasma exposure of the compound by the topical application was evaluated to range approximately 0.5–10 ng/mL. Conclusions: Rifampicin was delivered to the sub-retina in rabbits with an efficiency greater than the effective dose required for inhibiting neovascularization. Limited amounts of plasma exposure by the topical application were detected. These results suggested the therapeutic potential of the rifampicin formulations for the topical treatment of exudative macular degeneration.
- 29 April 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (5) , 655
Open AccessDevelopment of Rifampicin Eye Drops for the Treatment of Exudative Age-Related Macular Degeneration
Background/Objectives: Exudative age-related macular degeneration (AMD) is a disease of choroidal neovascularization that causes blindness. Current treatments to preserve vision in this prevalent and blinding condition are repeat intraocular injections of anti-vascular endothelial growth factor medicines for a patient’s lifetime to preserve and prevent vision loss leading to blindness. Rifampicin, a small-molecule antibiotic, has previously been reported to exhibit anti-angiogenic properties and a topical safety profile that is well-tolerated. Based on this evidence, we investigated the feasibility of formulating rifamycin as an ophthalmic drop capable of delivering therapeutic concentrations to the posterior segment of the eye. Methods: Inhibition of neovascularization by administration of rifampicin was analyzed in the rat oxygen-induced retinopathy (OIR) and mouse laser-induced choroidal neovascularization (CNV) models. Pharmacokinetic (PK) studies were conducted in mice, rats, and rabbits by dosing various formulations containing rifampicin, and the compound was quantified by LC/MS analysis. Results: Results from dose escalation studies in the mouse laser-induced CNV model suggested the minimum effective dose of rifampicin required for inhibiting neovascularization in subretinal tissues to be 0.7 mg/kg, which is substantially lower than the 20 mg/kg dosage approved for infectious disease treatments. The previous studies did not report the minimum effective dose in the anti-angiogenesis effects. The effective area under the concentration-time curve (AUC) in the sub-retina was evaluated as 0.27 h·ng/mg. In rabbits, rifampicin was delivered to the sub-retina by a single topical application of various formulations in a dose-dependent manner. The topical application of the formulations containing 1% rifampicin, which was well-tolerated in clinical trials previously reported for ocular trachoma, achieved subretinal delivery approximately 2–32 times greater than the effective AUC. Plasma exposure of the compound by the topical application was evaluated to range approximately 0.5–10 ng/mL. Conclusions: Rifampicin was delivered to the sub-retina in rabbits with an efficiency greater than the effective dose required for inhibiting neovascularization. Limited amounts of plasma exposure by the topical application were detected. These results suggested the therapeutic potential of the rifampicin formulations for the topical treatment of exudative macular degeneration.
- Open Access
Correlation Between Fixed-Luminance Flicker Full-Field Electroretinogram Response and Macular Cone Density in Healthy Individuals
This is the studyto investigate the correlation between macular cone density (MCD) and flicker electroretinogram (ERG) response in healthy eyes. In this exploratory study, 23 eyes from 12 healthy subjects were enrolled in this study. The fixed-luminance flicker full-field electroretinogram (ffERG) responses of the retina and MCDs at 24 locations were measured using the Diopsys® NOVA™ system and the rtx1 adaptive optics retinal camera, respectively. Regression analysis was employed to evaluate the correlations. The mean age of the subjects was 30 ± 3 years. The average magnitudes of the flicker response and phase response were 13.44 ± 4.88 μV and 332.63 ± 22.12°, respectively. The MCDs for all 24 locations were 15,043 ± 3511 cones/mm². Among all locations, regression analysis revealed a significant correlation only at one specific location (0, −4°) between cone density and both the mean magnitude and phase of the flicker response, with p-values of 0.005 and 0.004, respectively.In conclusion, we identified a significant correlation between MCD and ffERG responses at a specific retinal locus (0, −4°). This finding may be attributed to the distribution of different cone types throughout the retina and the possibility that various cone types may contribute differently to ERG. Further studies are required to investigate this finding.
Open AccessCorrelation Between Fixed-Luminance Flicker Full-Field Electroretinogram Response and Macular Cone Density in Healthy Individuals
This is the studyto investigate the correlation between macular cone density (MCD) and flicker electroretinogram (ERG) response in healthy eyes. In this exploratory study, 23 eyes from 12 healthy subjects were enrolled in this study. The fixed-luminance flicker full-field electroretinogram (ffERG) responses of the retina and MCDs at 24 locations were measured using the Diopsys® NOVA™ system and the rtx1 adaptive optics retinal camera, respectively. Regression analysis was employed to evaluate the correlations. The mean age of the subjects was 30 ± 3 years. The average magnitudes of the flicker response and phase response were 13.44 ± 4.88 μV and 332.63 ± 22.12°, respectively. The MCDs for all 24 locations were 15,043 ± 3511 cones/mm². Among all locations, regression analysis revealed a significant correlation only at one specific location (0, −4°) between cone density and both the mean magnitude and phase of the flicker response, with p-values of 0.005 and 0.004, respectively.In conclusion, we identified a significant correlation between MCD and ffERG responses at a specific retinal locus (0, −4°). This finding may be attributed to the distribution of different cone types throughout the retina and the possibility that various cone types may contribute differently to ERG. Further studies are required to investigate this finding.
- Top Cited PapersOpen Access
- 1 March 2024
- Published by Wolters Kluwer Health in Retina
- Vol. 44 (3) , 487-497
LIGHTSITE III
Purpose: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD) using the LumiThera Valeda Light Delivery System. Methods: LIGHTSITE III is a randomized, controlled trial to assess the safety and effectiveness of PBM in dry AMD. Subjects were given multiwavelength PBM (590, 660, and 850 nm) or Sham treatment delivered in a series of nine sessions over 3 to 5 weeks every four months over 24 months. Subjects were assessed for efficacy and safety outcomes. Data from the 13-month analysis are presented in this report. Results: A total of 100 subjects (148 eyes) with dry AMD were randomized. LIGHTSITE III met the primary efficacy best-corrected visual acuity endpoint with a significant difference between PBM (n = 91 eyes) and Sham (n = 54 eyes) groups (Between group difference: 2.4 letters (SE 1.15), CI: −4.7 to −0.1, P = 0.02) (PBM alone: 5.4 letters (SE 0.96), CI: 3.5 to 7.3, P < 0.0001; Sham alone: 3.0 letters (SE 1.13), CI: 0.7–5.2, P < 0.0001). The PBM group showed a significant decrease in new onset geographic atrophy (P = 0.024, Fisher exact test, odds ratio 9.4). A favorable safety profile was observed. Conclusion: LIGHTSITE III provides a prospective, randomized, controlled trial showing improved clinical and anatomical outcomes in intermediate dry AMD following PBM therapy.
- 1 March 2024
- Published by Wolters Kluwer Health in Retina
- Vol. 44 (3) , 487-497
Top Cited PapersOpen AccessLIGHTSITE III
Purpose: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD) using the LumiThera Valeda Light Delivery System. Methods: LIGHTSITE III is a randomized, controlled trial to assess the safety and effectiveness of PBM in dry AMD. Subjects were given multiwavelength PBM (590, 660, and 850 nm) or Sham treatment delivered in a series of nine sessions over 3 to 5 weeks every four months over 24 months. Subjects were assessed for efficacy and safety outcomes. Data from the 13-month analysis are presented in this report. Results: A total of 100 subjects (148 eyes) with dry AMD were randomized. LIGHTSITE III met the primary efficacy best-corrected visual acuity endpoint with a significant difference between PBM (n = 91 eyes) and Sham (n = 54 eyes) groups (Between group difference: 2.4 letters (SE 1.15), CI: −4.7 to −0.1, P = 0.02) (PBM alone: 5.4 letters (SE 0.96), CI: 3.5 to 7.3, P < 0.0001; Sham alone: 3.0 letters (SE 1.13), CI: 0.7–5.2, P < 0.0001). The PBM group showed a significant decrease in new onset geographic atrophy (P = 0.024, Fisher exact test, odds ratio 9.4). A favorable safety profile was observed. Conclusion: LIGHTSITE III provides a prospective, randomized, controlled trial showing improved clinical and anatomical outcomes in intermediate dry AMD following PBM therapy.
- Open Access
- 3 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (21) , 3376
Structural and Functional Changes in Non-Paraneoplastic Autoimmune Retinopathy
Background: To describe longitudinal changes in patients with non-paraneoplastic autoimmune retinopathy (npAIR) by utilizing different diagnostic modalities/tests. Methods: The index study is a retrospective longitudinal review of sixteen eyes of eight patients from a tertiary care eye hospital diagnosed with npAIR. Multiple diagnostic modalities such as wide-angle fundus photography (WAFP), WA fundus autofluorescence (WAFAF), spectral-domain optical coherence tomography (SD-OCT), Goldmann visual field (GVF) perimetry, microperimetry (MP), electrophysiologic testing, and adaptive optics scanning laser ophthalmoscopy (AOSLO) were reviewed and analyzed. Results: At the baseline visits, anomalies were detected by multimodal diagnostic tests on all patients. Subjects were followed up for a median duration of 11.5 [3.0–18.7] months. Structural changes at the baseline were detected in 14 of 16 (87.5%) eyes on WAFP and WAFAF and 13 of 16 (81.2%) eyes on SD-OCT. Eight of the ten (80%) eyes that underwent AOSLO imaging depicted structural changes. Functional changes were detected in 14 of 16 (87.5%) eyes on GVF, 15 of 16 (93.7%) eyes on MP, and 11 of 16 (68.7%) eyes on full-field electroretinogram (ff-ERG). Multifocal electroretinogram (mf-ERG) and visual evoked potential (VEP) tests were performed in 14 eyes, of which 12 (85.7%) and 14 (100%) of the eyes demonstrated functional abnormalities, respectively, at baseline. Compared to all the other structural diagnostic tools, AOSLO had a better ability to demonstrate deterioration in retinal microstructures occurring at follow-ups. Functional deterioration at follow-up was detected on GVF in 8 of 10 (80%) eyes, mf-ERG in 4 of 8 (50%) eyes, and MP in 7 of 16 (43.7%) eyes. The ff-ERG and VEP were stable in the majority of cases at follow-up. Conclusions: The utilization of multimodal imaging/tests in the diagnosing and monitoring of npAIR patients can aid in identifying anomalous changes over time. Analysis of both the anatomical and functional aspects by these devices can be supportive of detecting the changes early in such patients. AOSLO shows promise as it enables the capture of high-resolution images demonstrating quantifiable changes to retinal microstructure.
- 3 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (21) , 3376
Open AccessStructural and Functional Changes in Non-Paraneoplastic Autoimmune Retinopathy
Background: To describe longitudinal changes in patients with non-paraneoplastic autoimmune retinopathy (npAIR) by utilizing different diagnostic modalities/tests. Methods: The index study is a retrospective longitudinal review of sixteen eyes of eight patients from a tertiary care eye hospital diagnosed with npAIR. Multiple diagnostic modalities such as wide-angle fundus photography (WAFP), WA fundus autofluorescence (WAFAF), spectral-domain optical coherence tomography (SD-OCT), Goldmann visual field (GVF) perimetry, microperimetry (MP), electrophysiologic testing, and adaptive optics scanning laser ophthalmoscopy (AOSLO) were reviewed and analyzed. Results: At the baseline visits, anomalies were detected by multimodal diagnostic tests on all patients. Subjects were followed up for a median duration of 11.5 [3.0–18.7] months. Structural changes at the baseline were detected in 14 of 16 (87.5%) eyes on WAFP and WAFAF and 13 of 16 (81.2%) eyes on SD-OCT. Eight of the ten (80%) eyes that underwent AOSLO imaging depicted structural changes. Functional changes were detected in 14 of 16 (87.5%) eyes on GVF, 15 of 16 (93.7%) eyes on MP, and 11 of 16 (68.7%) eyes on full-field electroretinogram (ff-ERG). Multifocal electroretinogram (mf-ERG) and visual evoked potential (VEP) tests were performed in 14 eyes, of which 12 (85.7%) and 14 (100%) of the eyes demonstrated functional abnormalities, respectively, at baseline. Compared to all the other structural diagnostic tools, AOSLO had a better ability to demonstrate deterioration in retinal microstructures occurring at follow-ups. Functional deterioration at follow-up was detected on GVF in 8 of 10 (80%) eyes, mf-ERG in 4 of 8 (50%) eyes, and MP in 7 of 16 (43.7%) eyes. The ff-ERG and VEP were stable in the majority of cases at follow-up. Conclusions: The utilization of multimodal imaging/tests in the diagnosing and monitoring of npAIR patients can aid in identifying anomalous changes over time. Analysis of both the anatomical and functional aspects by these devices can be supportive of detecting the changes early in such patients. AOSLO shows promise as it enables the capture of high-resolution images demonstrating quantifiable changes to retinal microstructure.
- 17 March 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 7 (7) , 645-648
Consistency of Treatment Effect with Aflibercept by Baseline Factors in PANORAMA
- 17 March 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 7 (7) , 645-648
Consistency of Treatment Effect with Aflibercept by Baseline Factors in PANORAMA
- 1 October 2022
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 53 (10) , 579-581
Wide-Field Swept-Source Optical Coherence Tomography of Optic Disc Pit Maculopathy Demonstrates Connection Between Vitreous and Subretinal Fluid
The source of subretinal or intraretinal fluid in patients with optic disc pit maculopathy (ODP-M) remains unclear and is often thought to be either vitreous or cerebrospinal fluid.1 Here, we present the case of a 40-year-old man who developed ODP-M. Further imaging with wide-field swept-source optical coherence tomography demonstrated that the macular fluid was tracking from a nasal optic disc pit with superonasal communication to the vitreous. This suggests that swept-source optical coherence tomography can be a useful tool for determining the origin of macular fluid in patients with ODP-M. [Ophthalmic Surg Lasers Imaging Retina 2022;53:579–581.]
- 1 October 2022
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 53 (10) , 579-581
Wide-Field Swept-Source Optical Coherence Tomography of Optic Disc Pit Maculopathy Demonstrates Connection Between Vitreous and Subretinal Fluid
The source of subretinal or intraretinal fluid in patients with optic disc pit maculopathy (ODP-M) remains unclear and is often thought to be either vitreous or cerebrospinal fluid.1 Here, we present the case of a 40-year-old man who developed ODP-M. Further imaging with wide-field swept-source optical coherence tomography demonstrated that the macular fluid was tracking from a nasal optic disc pit with superonasal communication to the vitreous. This suggests that swept-source optical coherence tomography can be a useful tool for determining the origin of macular fluid in patients with ODP-M. [Ophthalmic Surg Lasers Imaging Retina 2022;53:579–581.]